ARS Pharmaceuticals, Inc.
Clinical trials sponsored by ARS Pharmaceuticals, Inc., explained in plain language.
Biopharmaceutical company developing treatments for severe allergic reactions.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Nasal spray vs. needle: new study tests easier allergy rescue Results expected Apr 2027 (estimated)
- New hives drug shows promise in early trial Results expected Jun 2027 (estimated)
-
Asthma rescue without needles: nasal spray could replace shots
Disease control CompletedThis phase 2 trial tests a needle-free epinephrine nasal spray (ARS-1) for managing asthma symptoms. People with persistent asthma receive a single dose of ARS-1, albuterol, or placebo in random order. The study measures how well the spray improves lung function compared to stand…
Phase 2 • Sponsor: ARS Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Nasal spray may offer fast hives relief without needles
Symptom relief CompletedThis study tested a single dose of a nasal spray called ARS-1 (intranasal epinephrine) in 21 adults who get frequent hives and itching. The goal was to see if the spray works faster and better than a placebo at reducing itch and hive scores during flare-ups. Participants were mon…
Phase 2 • Sponsor: ARS Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC